Protara Therapeutics, Inc. — Director's Dealing 2017

Mar 13, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PROTEON THERAPEUTICS INC (PRTO)
CIK: 0001359931
Period of Report: 2017-03-10

Reporting Person: Burke Steven Keith (SVP and Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-03-10	Common Stock	M	12287	$2.38	Acquired	37601	Direct
2017-03-10	Common Stock	M	57934	$1.27	Acquired	95535	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-03-10	Stock Option (Right to Buy)	$2.38	M	12287	Disposed	2017-09-09	Common Stock, $0.001 par value (12287)	Direct
2017-03-10	Stock Option (Right to Buy)	$1.27	M	57934	Disposed	2021-10-25	Common Stock, $0.001 par value (57934)	Direct

Footnotes

F1: The option was granted on September 10, 2007. All shares underlying the option have vested.

F2: The option was granted on October 26, 2011. All shares underlying the option have vested.